Evidence map›Paper›PMID 40954250›Full record

ArticleNature immunology2025

A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma.

Augusto Faria Andrade, Romain Sigaud, Evan Puligandla, Bridget Liu, Elham Karimi, Alva Annett, Morteza Rezanejad, Wajih Jawhar, Robert Taylor, Yi Cao and 21 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Decoding the Prognosis-Related S100A9OncoTargets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Augusto Faria Andrade *Charbonneau Cancer Institute, Cumming School of Medicine, Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.ORCID http://orcid.org/0000-0001-5866-0501
Romain Sigaud *University Hospital Jena, Department of Pediatrics and Adolescent Medicine, Friedrich Schiller University Jena, Jena, Germany.ORCID http://orcid.org/0000-0002-8600-8876
Evan Puligandla *Department of Human Genetics, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-8449-9221
Bridget LiuRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada.
Elham KarimiRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada.
Alva AnnettDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0002-3258-4296
Morteza RezanejadRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada.
Wajih JawharDivision of Experimental Medicine, Department of Medicine, McGill University, Montreal, Canada.ORCID http://orcid.org/0000-0002-2724-6401
Robert TaylorDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.
Yi CaoDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0009-0000-7350-5681
Simone SchmidDepartment of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Florian SeltHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Pablo Hernáiz DrieverCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German HIT-LOGGIC-Registry for pLGG in children and adolescents, Department of Pediatric Oncology and Hematology, Berlin, Germany.
Svea HornCharité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German HIT-LOGGIC-Registry for pLGG in children and adolescents, Department of Pediatric Oncology and Hematology, Berlin, Germany.
Philipp SieversHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-3237-6021
Marco PrinzInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-0349-1955
Markus GlatzelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-7720-8817
Christian MawrinDepartment of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Christian HartmannDepartment of Neuropathology, Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany.
Camelia-Maria MonoranuInstitute of Pathology, Department of Neuropathology, University of Wuerzburg, Comprehensive Cancer Center (CCC) Mainfranken Wuerzburg, Wuerzburg, Germany.
Liza KonnikovaDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4804-5497
Felix SahmHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5441-1962
Stefan M PfisterHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5447-5322
Olaf WittHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
David T W JonesHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Arend KochDepartment of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Claudia L KleinmanDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.
David CapperDepartment of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Logan WalshDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada. logan.walsh@mcgill.ca.ORCID http://orcid.org/0000-0001-8771-2577
Nada JabadoDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada. nada.jabado@mcgill.ca.ORCID http://orcid.org/0000-0003-2485-3692
Till MildeUniversity Hospital Jena, Department of Pediatrics and Adolescent Medicine, Friedrich Schiller University Jena, Jena, Germany. till.milde@med.uni-jena.de.ORCID http://orcid.org/0000-0002-7267-1052

Funding

Peripheral Immune Development in Premature Infants with and without NECR21HD102565 · NICHD · YALE UNIVERSITY · PI KONNIKOVA, LIZA, TSENG, GEORGE C. · 2020 to 2021
$456k
Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) FDN-154307NICHD NIH HHS R21 HD102565
6 · The paper itself

Abstract

Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells-including resident microglia and bone marrow-derived macrophages-as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid-myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3

Indexed as

Brain NeoplasmsGliomaMitogen-Activated Protein KinasesMyeloid CellsAdolescentChildChild, PreschoolFemaleHepatitis A Virus Cellular Receptor 2HumansInfantMacrophagesMaleMAP Kinase Signaling SystemNeoplasm GradingSingle-Cell AnalysisHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Mitogen-Activated Protein Kinases

Identifiers

PMID40954250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.